Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + FOLFIRI in untreated advanced colorectal cancer (GOIM)
2006-002887-25Phase 2Active
- Sponsor
- GOIM
- Start
- Jun 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, irinotecan, fluorouracil and levoleucovorin in colorectal cancer (CRC), sponsored by GOIM. Primary endpoint: Objectively confirmed response rate. Started Jun 2007; status: active.
02
Drugs
bevacizumabirinotecanfluorouracillevoleucovorin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-002887-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002887-25.